We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
+11.88%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$3.92B
AUM Growth
-$2.46M
Cap. Flow
-$121M
Cap. Flow %
-3.08%
Top 10 Hldgs %
77.48%
Holding
132
New
21
Increased
29
Reduced
29
Closed
20

Top Buys

Rank Stock Value
1
LXRX icon
Lexicon Pharmaceuticals
LXRX
+$103M
2
CGEM icon
Cullinan Oncology
CGEM
+$22.5M
3
RNAM
Avidity Biosciences
RNAM
+$18.8M
4
VERA icon
Vera Therapeutics
VERA
+$16.3M
5
JBIO
Jade Biosciences
JBIO
+$15.3M

Top Sells

Rank Stock Value
1
CAVA icon
CAVA Group
CAVA
+$232M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$29.5M
3
VKTX icon
Viking Therapeutics
VKTX
+$20.8M
4
ALPN
Alpine Immune Sciences Inc
ALPN
+$16.1M
5
ONC
BeOne Medicines Ltd
ONC
+$15.6M

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 56.02%
2 Healthcare 41.9%
3 Technology 0.98%
4 Financials 0.15%
5 Consumer Staples 0.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SE icon
51
Sea Limited
SE
$75.5B
$6.96M 0.18%
97,500
-140,000
-59% -$9.25M
PDD icon
52
Pinduoduo
PDD
$120B
$6.05M 0.15%
45,500
-11,000
-19% -$1.49M
NVDA icon
53
NVIDIA
NVDA
$5.46T
$5.31M 0.14%
43,000
+24,000
+126% +$2.43M
MSFT icon
54
Microsoft
MSFT
$3.69T
$5.05M 0.13%
11,300
+8,800
+352% +$3.72M
V icon
55
Visa
V
$682B
$4.99M 0.13%
19,000
+16,500
+660% +$4.52M
BDTX icon
56
Black Diamond Therapeutics
BDTX
$116M
$4.88M 0.12%
1,046,517
– –
DT icon
57
Dynatrace
DT
$14.7B
$4.88M 0.12%
109,000
+73,000
+203% +$3.36M
KLRS
58
Kalaris Therapeutics
KLRS
$92.4M
$4.77M 0.12%
286,833
– –
APLT
59
DELISTED
Applied Therapeutics
APLT
$4.71M 0.12%
1,009,500
– –
TSM icon
60
TSMC
TSM
$2.23T
$4.52M 0.12%
26,000
-6,000
-19% -$910K
FHTX icon
61
Foghorn Therapeutics
FHTX
$385M
$4.14M 0.11%
720,720
– –
DDOG icon
62
Datadog
DDOG
$90.6B
$3.75M 0.1%
28,925
+19,325
+201% +$2.34M
ANRO icon
63
Alto Neuroscience
ANRO
$1.26B
$3.74M 0.1%
350,000
– –
AMZN icon
64
Amazon
AMZN
$2.86T
$3.72M 0.09%
19,250
+7,250
+60% +$1.33M
FATE icon
65
Fate Therapeutics
FATE
$294M
$3.39M 0.09%
1,032,500
+672,189
+187% +$2.94M
HOOK
66
DELISTED
HOOKIPA Pharma
HOOK
$3.35M 0.09%
566,641
– –
ADCT icon
67
ADC Therapeutics
ADCT
$134M
$3.22M 0.08%
+1,018,461
New +$4.05M
BEKE icon
68
KE Holdings
BEKE
$18.7B
$3.18M 0.08%
225,000
-50,000
-18% -$783K
RGNX icon
69
Regenxbio
RGNX
$704M
$2.92M 0.07%
250,000
– –
OMGA
70
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
$2.74M 0.07%
1,323,530
– –
ELEV
71
DELISTED
Elevation Oncology
ELEV
$2.74M 0.07%
1,013,015
-500,000
-33% -$1.88M
KVUE icon
72
Kenvue
KVUE
$36.9B
$2.49M 0.06%
+137,000
New +$2.65M
SGMT icon
73
Sagimet Biosciences
SGMT
$577M
$2.48M 0.06%
724,771
– –
CBIO
74
Crescent Biopharma
CBIO
$618M
$2.42M 0.06%
85,891
– –
PCOR icon
75
Procore
PCOR
$9.45B
$2.14M 0.05%
32,300
+22,800
+240% +$1.58M
1 2
3
4 5

Similar funds

GP
Greenline Partners New York $930M AUM 29.59% 1-Year Est. Return
BCC
Biglari Capital Corp San Antonio, Texas $929M AUM 39.8% 1-Year Est. Return
FPI
Financial Plan Inc Bellingham, Washington $933M AUM
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
ICM
Innovator Capital Management Wheaton, Illinois $925M AUM 49.11% 1-Year Est. Return
OCM
OLP Capital Management Causeway Bay, Hong Kong $942M AUM 5.25% 1-Year Est. Return

Artal Group's Q2 2024 Portfolio in Review

As of Q2 2024, Artal Group held 132 positions worth $3.92B, down 0.06% from $3.93B the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Artal Group withdrew a net $121M in Q2 2024, closing 20 positions and reducing 29 holdings. Its most notable exit was Madrigal Pharmaceuticals, an estimated $29.5M position sold in full.

By sector, the portfolio is most concentrated in Consumer Discretionary at 56% of assets, up from 48% a quarter earlier, followed by Healthcare and Technology.

Against the trend, Artal Group opened a new position in Cullinan Oncology worth $18.5M.

  • Artal Group's largest Q2 2024 buy was Cullinan Oncology: 1,057,949 shares worth $18.5M.
  • Artal Group added most to Lexicon Pharmaceuticals in Q2 2024, an estimated $103M increase.
  • Artal Group's biggest Q2 2024 reduction was CAVA Group, cutting an estimated $232M.
  • Artal Group fully exited Madrigal Pharmaceuticals in Q2 2024, selling an estimated $29.5M.
  • Artal Group's ten largest holdings make up 77% of its $3.92B portfolio in Q2 2024.
  • Artal Group opened 21 new positions and closed 20 in Q2 2024.
  • Artal Group's portfolio value fell 0.06% quarter-over-quarter to $3.92B.

Based on Artal Group's 13F filing for Q2 2024, filed 14 Aug 2024.